Illness severity, advanced age, and chronic liver disease were strong predictors of 30-day mortality among hospitalized patients with CAP.

Omadacycline has a high clinical success rate for treating community-acquired bacterial pneumonia (CABP), according to results of a study presented at IDWeek 2025, held from October 19 to 22, in ...

Adjuvant ensartinib improves disease-free survival compared to placebo following complete resection of ALK-positive non-small cell lung cancer.

The FDA has approved Kygevvi (doxecitine and doxribtimine) for the treatment of TK2d in adults and pediatric patients with an age of symptom onset on or before 12 years.

Presenting research from the American College of Allergy, Asthma, and Immunology.